迪布罗莫-埃达拉通过JAK2-STAT3信号通路诱导抗红血病效应
Qiqing Chen1,2,3, Sheng Liu1,2, Xuenai Wei1,2,3
1State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang 550014, China.
International journal of molecular sciences
|May 14, 2025
概括
迪布罗莫-埃达拉 (D-EDA) 通过诱导亡和抑制关键信号通路,对急性红色素白血病 (AEL) 产生强大的抗白血病作用. 这种新型药物在体外和体内都显示出有效性,为AEL提供了潜在的新疗法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性红细胞白血病 (AEL) 是一种具有有限治疗选择的侵袭性恶性瘤.
- 目前针对AEL的治疗方法面临着药物耐药性和高毒性等挑战.
- 对于对抗AEL的新型治疗策略有着至关重要的需求.
研究的目的:
- 为了研究新型埃达拉衍生物双-埃达拉 (D-EDA) 的抗白血病特性.
- 阐明D-EDA对AEL细胞影响的机制.
- 评估D-EDA在AEL临床前模型中的治疗潜力.
主要方法:
- 在体外细胞毒性测定 (MTT) 和用D-EDA.治疗的HEL细胞的形态分析.
- 流细胞计,何氏33258,吉姆萨,JC-1和ROS试验,以评估细胞亡和细胞循环效应.
- 西方斑分析用于评估与亡相关的蛋白质和瘤标记物.
- 包括分子对接,CETSA和途径抑制剂 (JAK2,STAT3) 在内的机制研究.
- 在体内研究使用AEL小鼠模型来评估治疗疗效.
主要成果:
- D-EDA对HEL细胞表现出强烈的细胞毒性 (IC50 = 8.17μM),并诱导显著的细胞亡.
- D-EDA导致S阶段细胞循环停止和调节与亡相关的蛋白质 (caspase激活,PARP裂变,Bcl-2下调).
- 在D-EDA下调的瘤标志物 (c-Myc,CyclinA2,CDK2) 和上调的p21.
- 机理学研究表明,D-EDA激活了酶级联并抑制了JAK2-STAT3通路.
- 在体内,D-EDA改善了脏结构,增加了血液溶解,并在AEL小鼠模型中延长了生存时间.
结论:
- 通过酶激活和JAK2-STAT3通路的抑制,D-EDA有效地诱导AEL细胞的亡.
- D-EDA在体外和体内都显示出显著的抗白血病活性.
- D-EDA 是一种有前途的治疗候选药物,用于治疗急性红细胞白血病.
相关概念视频
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
MAPK Signaling Cascades
5.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
107
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
107


